C-IR7VRF Longevity
TRFT, transcranial radiofrequency waves, bioengineering
clearingdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IR7V
C-IR7VC-IR7VTRFT, transcranial radiofrequency waves, bioengineering
0-100 chain-logic scale · 15 dimensions · scored on public evidence
RF Longevity TRFT, transcranial radiofrequency waves, bioengineering
RF Longevity presents transcranial radiofrequency waves as a bioengineered intervention intended to increase healthy human longevity. The site contrasts this device-based approach with gerotherapeutic drugs such as metformin, NAD precursors, rapamycin, and dasatinib plus quercetin. Gary W. Arendash, Ph.D. is identified as principal of RF Longevity SE.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
RF Longevity — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (4 programs at exploratory).…
Source: Deterministic